ProKidney Corp
PROKBuild a strategy around PROK
ProKidney Corp AI Insights
Informational only. Not investment advice.Snapshot
- Negative equity of -1.0B with only 95.3M cash and -146.7M FCF TTM implies 6-8 month runway without additional financing.[Free Cash Flow TTM]
- R&D of 119.7M TTM is 161x revenue (0.7M) - pure clinical-stage biotech with no commercial operations.[Research and Development TTM]
- P/S ratio of 401x vs industry median 2.7x reflects speculative valuation on pre-revenue pipeline.[Price to Sales Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 50M or no financing announced within 6 months — At -147M FCF, sub-50M cash signals <4 months runway - bankruptcy risk.
- Issuance of Capital Stock: New equity raise announced — Dilution inevitable; terms and size determine shareholder impact.
- Research and Development TTM: Significant reduction (>30%) — R&D cuts may signal pipeline failure or pivot away from core thesis.
Bull Case
Working capital of 270.9M and minimal debt (4.2M) provides near-term operational flexibility while awaiting clinical catalysts.
R&D intensity (119.7M) signals serious pipeline investment; positive investment sale activity (112.8M) shows liquidity management.
Bear Case
Negative equity (-1.0B) and -147M annual cash burn with only 95M cash creates imminent dilution or insolvency risk.
P/S of 401x on 0.7M revenue is entirely speculative; any clinical setback collapses valuation.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage PROK's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary outcome: clinical success drives 5-10x upside, failure means near-total loss.
- Zero commercial revenue - entirely dependent on pipeline
- Cash burn of ~147M/year requires dilutive financing
- Negative 1B equity creates existential balance sheet risk
Valuation Context
Caveats
Public Strategies Rankings
See how ProKidney Corp ranks across different investment strategies.
Leverage PROK's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
PROK Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$0 | — | ||
$0 | — | ||
0.00 | — | ||
$893,000 | +1075.0% | — | |
$0.00 | — | ||
-18,478% | +223201.1% | — | |
-7,725% | +72782.7% | — | |
$-135.31M | — | ||
0% | — | ||
Beta 5Y (Monthly) | unknown | — |
PROK Dividend History
PROK Stock Splits
PROK SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/18/26 | 12/31/25 | 10-K | |
11/10/25 | 09/30/25 | 10-Q | |
08/12/25 | 06/30/25 | 10-Q | |
05/12/25 | 03/31/25 | 10-Q | |
03/17/25 | 12/31/24 | 10-K | |
11/12/24 | 09/30/24 | 10-Q | |
08/09/24 | 06/30/24 | 10-Q | |
05/10/24 | 03/31/24 | 10-Q | |
03/22/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/10/23 | 06/30/23 | 10-Q | |
05/11/23 | 03/31/23 | 10-Q | |
03/28/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/26/22 | 06/30/22 | S-1/A | |
06/10/22 | 03/31/22 | DEFM14A | |
06/10/22 | 12/31/21 | DEFM14A | |
11/14/22 | 09/30/21 | 10-Q | |
08/26/22 | 06/30/21 | S-1/A | |
06/10/22 | 03/31/21 | DEFM14A |